We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Rigel Suffers More Clinical Trial Disappointments

Rigel Suffers More Clinical Trial Disappointments

August 21, 2014

Rigel Pharmaceuticals said it will not initiate any new studies of R348 for the treatment of dry eye disease, after the compound failed to meet its primary and secondary endpoints in a recently completed Phase II trial.

The San Francisco drugmaker will, however, continue its Phase II study of dry eye in patients with graft versus host disease.

The endpoints were measured by changes in corneal fluorescein staining, tear production and dry eye symptoms over 12 weeks compared with a placebo, the company said.

Rigel also halted development of R118 — an AMP-activated protein kinase inhibitor intended to treat peripheral artery disease — due to its side effect profile in a Phase I clinical trial.
The latest setbacks are “disappointing,” but not back-breaking for the company, says Brian Abrahams, a senior analyst with Wells Fargo.

“We believe expectations were relatively low for the [R348] program given historical challenges in this indication,” he writes in a Wednesday research note. The company’s efforts to develop a compound called fostamatinib could help soften the blow, he adds.

Rigel recently started a Phase III trial of fostamatinib to treat patients with immune thrombocytopenic purpura, a bleeding disorder. A Phase II study of patients with the kidney autoimmune disease IgA Nephropathy is expected to launch by the end of this year.

Abrahams notes that fostamatinib already has an established safety profile.
AstraZeneca handed the rights to fostamatinib to Rigel last year after a late-stage trial for rheumatoid arthritis showed mixed results.

Rigel is no stranger to drug development setbacks. Last year, the company ditched a compound called R333 to treat skin lesions in patients with discoid lupus erythematosus because a Phase II trial didn’t meet an endpoint.

Rigel posted a net loss of $47.7 million for the first six months of 2014, according to its most recent financial report.

The drugmaker did not return a request for comment by press time. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Submissions and Approvals

    Upcoming Events

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Potential Penalties Force BMS to Sign Drug Price Negotiation Agreement With CMS

    • Despite AdComm Endorsement, neffy Nasal Spray Alternate for EpiPen Gets CRL

    • Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

    • Reports Allege Philips Withheld Evidence of Ventilator Malfunctions for 11 Years

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing